ENSC - Opioid Developer Ensysce Biosciences Stock Is Shooting Higher Today - Here's Why | Benzinga
Ensysce Biosciences Inc (NASDAQ:ENSC) received an FDA Breakthrough Therapy Designation (BTD) for PF614-MPAR, a next-generation opioid.
BTD has been granted to fewer than 300 drugs. It is designed to expedite the development and reviewing of drugs intended to treat a serious condition where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapies.
PF614-MPAR is designed to provide optimal pain relief at prescribed doses yet limit accidental or intentional overdose by ‘shutting down’ ...